Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003641 | High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma | completed | Phase 3 | 1,150 | ECOG-ACRIN Cancer Research GroupNETWORK | 4 | Sep 29, 2026 | clinicaltrials |
| NCT06014086 | Intratumoral PH-762 for Cutaneous Carcinoma | completed | Phase 1 | 22 | Phio Pharmaceuticals Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| Skin Cancer Among Outdoor Workers(Skin Cancer Am) |
| completed |
| — |
| 10,000 |
| Assuta Medical CenterOTHER |
| 1 |
| Sep 21, 2026 |
| clinicaltrials |
| NCT04544748 | A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | completed | Phase 1 | 48 | AO GENERIUMINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT01720407 | Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face(ImiReduc) | completed | Phase 3 | 259 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01840527 | Utility of Novel BRAF Test for Melanoma | completed | — | 220 | Massachusetts General HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02678572 | Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma(FOCUS) | completed | Phase 3 | 102 | Delcath Systems Inc.INDUSTRY | 9 | Sep 10, 2026 | clinicaltrials |
| NCT04796194 | Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma(ATLAS-IT-05) | completed | Phase 2 | 23 | Lytix Biopharma ASINDUSTRY | 4 | Sep 10, 2026 | clinicaltrials |
| NCT03584334 | 18FDG PET for Early Identification of Tumor Exhaust for Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Bronchopulmonary Carcinoma or Melanoma(FDG-IMMUN) | completed | N/A | 100 | Centre Antoine LacassagneOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02997553 | Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery(GASVERT) | completed | Phase 3 | 744 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03021460 | Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04305041 | Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 100 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT03743766 | Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting | completed | Phase 2 | 43 | John KirkwoodOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT03948724 | Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology(EDHITO) | completed | N/A | 412 | Institut Cancerologie de l'OuestOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT03131908 | Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss | completed | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04303169 | Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 146 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Aug 27, 2026 | clinicaltrials |
| NCT04670445 | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer(UPLIFT) | completed | N/A | 199 | Massachusetts General HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06384417 | Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2 | completed | N/A | 30 | Milton S. Hershey Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06549439 | eFLASH for Skin Lesions of Malignant Melanomas(Flash-Skin I) | completed | N/A | 7 | University of ZurichOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04370704 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | completed | Phase 1 / Phase 2 | 61 | Incyte CorporationINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT02581930 | Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07757386 | MelaMEd Online Training for General Practitioners to Improve Melanoma Detection and Management(MelaMEd) | completed | N/A | 1,531 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04386967 | OH2 Injection in Solid Tumors | completed | Phase 1 / Phase 2 | 44 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT01024231 | Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | completed | Phase 1 | 127 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 96 | HUYABIO International, LLC.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05282901 | Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)(PLUME) | completed | Phase 2 | 51 | Institut CurieOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT00429312 | A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma | completed | Phase 1 / Phase 2 | 10 | Jennerex BiotherapeuticsINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06666634 | Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy(NANOSCAN) | completed | N/A | 29 | The Netherlands Cancer InstituteOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT01708941 | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03225365 | Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma(IMMUNONIVO) | completed | N/A | 5 | Hospices Civils de LyonOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03405155 | Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06307093 | Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms | completed | Phase 1 | 90 | R-PharmINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06320353 | Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma | completed | Phase 3 | 266 | R-PharmINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02724488 | Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies(SPECIAL) | completed | — | 14 | University Health Network, TorontoOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT04201223 | Family Lifestyles, Actions, and Risk Education Intervention: Version 2(FLARE) | completed | N/A | 752 | University of UtahOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT02009449 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors(IVY) | completed | Phase 1 | 353 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04773951 | A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors | completed | Phase 1 | 47 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03472586 | Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver | completed | Phase 2 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06153238 | A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma | completed | Phase 1 | 322 | SandozINDUSTRY | 18 | Jul 7, 2026 | clinicaltrials |
| NCT04609566 | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | completed | Phase 2 | 161 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04401995 | Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab | completed | Phase 2 | 9 | Diwakar DavarOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07671495 | Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin(ATSMAIN) | completed | Phase 2 | 278 | MIPO ClinicOTHER | 0 | Jun 30, 2026 | clinicaltrials |
| NCT01972347 | Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma(Neo Combi) | completed | Phase 2 | 35 | Melanoma Institute AustraliaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04526730 | Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients | completed | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07670403 | Digital Phenotyping of Psychological Distress in Skin Cancer Patients(DP-SKIN) | completed | — | 500 | West China HospitalOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05712551 | Dermoscopy Augmented Histology Trial, Consensus Agreement Diagnosis Made by Dermatopathology Experts | completed | — | 4 | Herlev HospitalOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT01989572 | Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery | completed | Phase 3 | 815 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
Data updated 11 hours agoSource updated Sep 29, 2026source: clinicaltrials